secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016842
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Q2 net loss $17.1M; Phase 2b LSD trial for GAD on track; reverse split 1-for-15
--------------------------------------------------------------------------------

- Q2 2022 net loss $17.1M vs $44.5M in Q2 2021; R&D expense $9.3M (up $1.2M YoY).
- Cash $105.7M as of June 30, 2022; runway through key clinical readouts into 2024.
- Phase 2b MM-120 (LSD) trial for GAD underway; first patient dosing expected Q3 2022, topline late 2023.
- Board approved 1-for-15 reverse share split effective Aug 26, 2022; split-adjusted trading Aug 29.
- Appointed Drs. Suzanne Bruhn and Roger Crystal as independent directors; Miri Halperin Wernli retired from board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017022016842/0000950170-22-016842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017022016842/mnmd-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer